Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study
Next‐generation sequencing (NGS) of tumor tissue (ie, clinical sequencing) can guide clinical management by providing information about actionable gene aberrations that have diagnostic and therapeutic significance. Here, we undertook a hospital‐based prospective study (TOP‐GEAR project, 2nd stage) t...
Saved in:
| Published in | Cancer science Vol. 110; no. 4; pp. 1480 - 1490 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
John Wiley & Sons, Inc
01.04.2019
John Wiley and Sons Inc |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Next‐generation sequencing (NGS) of tumor tissue (ie, clinical sequencing) can guide clinical management by providing information about actionable gene aberrations that have diagnostic and therapeutic significance. Here, we undertook a hospital‐based prospective study (TOP‐GEAR project, 2nd stage) to investigate the feasibility and utility of NGS‐based analysis of 114 cancer‐associated genes (the NCC Oncopanel test). We examined 230 cases (comprising more than 30 tumor types) of advanced solid tumors, all of which were matched with nontumor samples. Gene profiling data were obtained for 187 cases (81.3%), 111 (59.4%) of which harbored actionable gene aberrations according to the Clinical Practice Guidelines for Next Generation Sequencing in Cancer Diagnosis and Treatment (Edition 1.0) issued by 3 major Japanese cancer‐related societies. Twenty‐five (13.3%) cases have since received molecular‐targeted therapy according to their gene aberrations. These results indicate the utility of tumor‐profiling multiplex gene panel testing in a clinical setting in Japan. This study is registered with UMIN Clinical Trials Registry (UMIN 000011141).
The results of the TOP‐GEAR project (UMIN 000011141) indicate the utility of tumor‐profiling multiplex gene panel testing in a clinical setting in Japan. |
|---|---|
| AbstractList | Next‐generation sequencing (
NGS
) of tumor tissue (ie, clinical sequencing) can guide clinical management by providing information about actionable gene aberrations that have diagnostic and therapeutic significance. Here, we undertook a hospital‐based prospective study (
TOP
‐
GEAR
project, 2nd stage) to investigate the feasibility and utility of
NGS
‐based analysis of 114 cancer‐associated genes (the
NCC
Oncopanel test). We examined 230 cases (comprising more than 30 tumor types) of advanced solid tumors, all of which were matched with nontumor samples. Gene profiling data were obtained for 187 cases (81.3%), 111 (59.4%) of which harbored actionable gene aberrations according to the Clinical Practice Guidelines for Next Generation Sequencing in Cancer Diagnosis and Treatment (Edition 1.0) issued by 3 major Japanese cancer‐related societies. Twenty‐five (13.3%) cases have since received molecular‐targeted therapy according to their gene aberrations. These results indicate the utility of tumor‐profiling multiplex gene panel testing in a clinical setting in Japan. This study is registered with
UMIN
Clinical Trials Registry (
UMIN
000011141). Next-generation sequencing (NGS) of tumor tissue (ie, clinical sequencing) can guide clinical management by providing information about actionable gene aberrations that have diagnostic and therapeutic significance. Here, we undertook a hospital-based prospective study (TOP-GEAR project, 2nd stage) to investigate the feasibility and utility of NGS-based analysis of 114 cancer-associated genes (the NCC Oncopanel test). We examined 230 cases (comprising more than 30 tumor types) of advanced solid tumors, all of which were matched with nontumor samples. Gene profiling data were obtained for 187 cases (81.3%), 111 (59.4%) of which harbored actionable gene aberrations according to the Clinical Practice Guidelines for Next Generation Sequencing in Cancer Diagnosis and Treatment (Edition 1.0) issued by 3 major Japanese cancer-related societies. Twenty-five (13.3%) cases have since received molecular-targeted therapy according to their gene aberrations. These results indicate the utility of tumor-profiling multiplex gene panel testing in a clinical setting in Japan. This study is registered with UMIN Clinical Trials Registry (UMIN 000011141).Next-generation sequencing (NGS) of tumor tissue (ie, clinical sequencing) can guide clinical management by providing information about actionable gene aberrations that have diagnostic and therapeutic significance. Here, we undertook a hospital-based prospective study (TOP-GEAR project, 2nd stage) to investigate the feasibility and utility of NGS-based analysis of 114 cancer-associated genes (the NCC Oncopanel test). We examined 230 cases (comprising more than 30 tumor types) of advanced solid tumors, all of which were matched with nontumor samples. Gene profiling data were obtained for 187 cases (81.3%), 111 (59.4%) of which harbored actionable gene aberrations according to the Clinical Practice Guidelines for Next Generation Sequencing in Cancer Diagnosis and Treatment (Edition 1.0) issued by 3 major Japanese cancer-related societies. Twenty-five (13.3%) cases have since received molecular-targeted therapy according to their gene aberrations. These results indicate the utility of tumor-profiling multiplex gene panel testing in a clinical setting in Japan. This study is registered with UMIN Clinical Trials Registry (UMIN 000011141). Next-generation sequencing (NGS) of tumor tissue (ie, clinical sequencing) can guide clinical management by providing information about actionable gene aberrations that have diagnostic and therapeutic significance. Here, we undertook a hospital-based prospective study (TOP-GEAR project, 2nd stage) to investigate the feasibility and utility of NGS-based analysis of 114 cancer-associated genes (the NCC Oncopanel test). We examined 230 cases (comprising more than 30 tumor types) of advanced solid tumors, all of which were matched with nontumor samples. Gene profiling data were obtained for 187 cases (81.3%), 111 (59.4%) of which harbored actionable gene aberrations according to the Clinical Practice Guidelines for Next Generation Sequencing in Cancer Diagnosis and Treatment (Edition 1.0) issued by 3 major Japanese cancer-related societies. Twenty-five (13.3%) cases have since received molecular-targeted therapy according to their gene aberrations. These results indicate the utility of tumor-profiling multiplex gene panel testing in a clinical setting in Japan. This study is registered with UMIN Clinical Trials Registry (UMIN 000011141). Next‐generation sequencing (NGS) of tumor tissue (ie, clinical sequencing) can guide clinical management by providing information about actionable gene aberrations that have diagnostic and therapeutic significance. Here, we undertook a hospital‐based prospective study (TOP‐GEAR project, 2nd stage) to investigate the feasibility and utility of NGS‐based analysis of 114 cancer‐associated genes (the NCC Oncopanel test). We examined 230 cases (comprising more than 30 tumor types) of advanced solid tumors, all of which were matched with nontumor samples. Gene profiling data were obtained for 187 cases (81.3%), 111 (59.4%) of which harbored actionable gene aberrations according to the Clinical Practice Guidelines for Next Generation Sequencing in Cancer Diagnosis and Treatment (Edition 1.0) issued by 3 major Japanese cancer‐related societies. Twenty‐five (13.3%) cases have since received molecular‐targeted therapy according to their gene aberrations. These results indicate the utility of tumor‐profiling multiplex gene panel testing in a clinical setting in Japan. This study is registered with UMIN Clinical Trials Registry (UMIN 000011141). The results of the TOP‐GEAR project (UMIN 000011141) indicate the utility of tumor‐profiling multiplex gene panel testing in a clinical setting in Japan. |
| Author | Taniguchi, Hirokazu Furukawa, Eisaku Kubo, Takashi Fujiwara, Yutaka Morizane, Chigusa Hiraoka, Nobuyoshi Kitami, Mayuko Yoshida, Hiroshi Nagai, Momoko Maeshima, Akiko Satomi, Kaishi Sunami, Kuniko Yoshida, Masayuki Ochiai, Atsushi Motoi, Noriko Tamura, Kenji Yoshida, Akihiko Fujiwara, Yasuhiro Tanabe, Noriko Shimizu, Toshio Kohno, Takashi Shimomura, Akihiko Matsushita, Hiromichi Koyama, Takafumi Kato, Mamoru Iwasa, Satoru Sugano, Kokichi Ogawa, Chitose Watanabe, Reiko Narushima, Daichi Yamamoto, Noboru Hashimoto, Taiki Sekine, Shigeki Mori, Taisuke Sukeda, Aoi Kakishima, Hiroki Kato, Ken Yonemori, Kan Yoshida, Teruhiko Ichikawa, Hitoshi |
| AuthorAffiliation | 1 Department of Pathology and Clinical Laboratories National Cancer Center Hospital Tokyo Japan 10 Oncogene Research Unit/Cancer Prevention Unit Tochigi Cancer Center Research Institute Tochigi Japan 2 Department of Clinical Genomics National Cancer Center Research Institute Tokyo Japan 14 Division of Genome Biology National Cancer Center Research Institute Tokyo Japan 13 Exploratory Oncology Research and Clinical Trial Center National Cancer Center Tokyo Japan 8 Department of Pediatric Oncology National Cancer Center Hospital Tokyo Japan 4 Department of Bioinformatics National Cancer Center Research Institute Tokyo Japan 9 Genetic Medicine and Services National Cancer Center Hospital Tokyo Japan 12 Strategic Planning Bureau National Cancer Center Tokyo Japan 3 Division of Translational Genomics Exploratory Oncology Research and Clinical Trial Center National Cancer Center Tokyo Japan 7 Department of Hepatobiliary and Pancreatic Oncology National Cancer Center Hospital Tokyo Japan 5 Department of |
| AuthorAffiliation_xml | – name: 1 Department of Pathology and Clinical Laboratories National Cancer Center Hospital Tokyo Japan – name: 3 Division of Translational Genomics Exploratory Oncology Research and Clinical Trial Center National Cancer Center Tokyo Japan – name: 2 Department of Clinical Genomics National Cancer Center Research Institute Tokyo Japan – name: 8 Department of Pediatric Oncology National Cancer Center Hospital Tokyo Japan – name: 6 Department of Gastrointestinal Medical Oncology National Cancer Center Hospital Tokyo Japan – name: 7 Department of Hepatobiliary and Pancreatic Oncology National Cancer Center Hospital Tokyo Japan – name: 5 Department of Experimental Therapeutics National Cancer Center Hospital Tokyo Japan – name: 4 Department of Bioinformatics National Cancer Center Research Institute Tokyo Japan – name: 11 Department of Breast and Medical Oncology National Cancer Center Hospital Tokyo Japan – name: 12 Strategic Planning Bureau National Cancer Center Tokyo Japan – name: 10 Oncogene Research Unit/Cancer Prevention Unit Tochigi Cancer Center Research Institute Tochigi Japan – name: 13 Exploratory Oncology Research and Clinical Trial Center National Cancer Center Tokyo Japan – name: 9 Genetic Medicine and Services National Cancer Center Hospital Tokyo Japan – name: 14 Division of Genome Biology National Cancer Center Research Institute Tokyo Japan |
| Author_xml | – sequence: 1 givenname: Kuniko surname: Sunami fullname: Sunami, Kuniko organization: National Cancer Center Hospital – sequence: 2 givenname: Hitoshi surname: Ichikawa fullname: Ichikawa, Hitoshi organization: National Cancer Center – sequence: 3 givenname: Takashi surname: Kubo fullname: Kubo, Takashi organization: National Cancer Center – sequence: 4 givenname: Mamoru surname: Kato fullname: Kato, Mamoru organization: National Cancer Center Research Institute – sequence: 5 givenname: Yutaka orcidid: 0000-0001-8972-9217 surname: Fujiwara fullname: Fujiwara, Yutaka organization: National Cancer Center Hospital – sequence: 6 givenname: Akihiko orcidid: 0000-0002-2557-8170 surname: Shimomura fullname: Shimomura, Akihiko organization: National Cancer Center Hospital – sequence: 7 givenname: Takafumi orcidid: 0000-0001-5807-8458 surname: Koyama fullname: Koyama, Takafumi organization: National Cancer Center Hospital – sequence: 8 givenname: Hiroki surname: Kakishima fullname: Kakishima, Hiroki organization: National Cancer Center Hospital – sequence: 9 givenname: Mayuko surname: Kitami fullname: Kitami, Mayuko organization: National Cancer Center Hospital – sequence: 10 givenname: Hiromichi surname: Matsushita fullname: Matsushita, Hiromichi organization: National Cancer Center Hospital – sequence: 11 givenname: Eisaku surname: Furukawa fullname: Furukawa, Eisaku organization: National Cancer Center Research Institute – sequence: 12 givenname: Daichi surname: Narushima fullname: Narushima, Daichi organization: National Cancer Center Research Institute – sequence: 13 givenname: Momoko surname: Nagai fullname: Nagai, Momoko organization: National Cancer Center Research Institute – sequence: 14 givenname: Hirokazu surname: Taniguchi fullname: Taniguchi, Hirokazu organization: National Cancer Center Hospital – sequence: 15 givenname: Noriko orcidid: 0000-0001-7098-3311 surname: Motoi fullname: Motoi, Noriko organization: National Cancer Center Hospital – sequence: 16 givenname: Shigeki surname: Sekine fullname: Sekine, Shigeki organization: National Cancer Center Hospital – sequence: 17 givenname: Akiko orcidid: 0000-0001-7251-7920 surname: Maeshima fullname: Maeshima, Akiko organization: National Cancer Center Hospital – sequence: 18 givenname: Taisuke surname: Mori fullname: Mori, Taisuke organization: National Cancer Center Hospital – sequence: 19 givenname: Reiko surname: Watanabe fullname: Watanabe, Reiko organization: National Cancer Center Hospital – sequence: 20 givenname: Masayuki surname: Yoshida fullname: Yoshida, Masayuki organization: National Cancer Center Hospital – sequence: 21 givenname: Akihiko surname: Yoshida fullname: Yoshida, Akihiko organization: National Cancer Center Hospital – sequence: 22 givenname: Hiroshi surname: Yoshida fullname: Yoshida, Hiroshi organization: National Cancer Center Hospital – sequence: 23 givenname: Kaishi surname: Satomi fullname: Satomi, Kaishi organization: National Cancer Center Hospital – sequence: 24 givenname: Aoi surname: Sukeda fullname: Sukeda, Aoi organization: National Cancer Center Hospital – sequence: 25 givenname: Taiki surname: Hashimoto fullname: Hashimoto, Taiki organization: National Cancer Center Hospital – sequence: 26 givenname: Toshio surname: Shimizu fullname: Shimizu, Toshio organization: National Cancer Center Hospital – sequence: 27 givenname: Satoru surname: Iwasa fullname: Iwasa, Satoru organization: National Cancer Center Hospital – sequence: 28 givenname: Kan surname: Yonemori fullname: Yonemori, Kan organization: National Cancer Center Hospital – sequence: 29 givenname: Ken surname: Kato fullname: Kato, Ken organization: National Cancer Center Hospital – sequence: 30 givenname: Chigusa surname: Morizane fullname: Morizane, Chigusa organization: National Cancer Center Hospital – sequence: 31 givenname: Chitose surname: Ogawa fullname: Ogawa, Chitose organization: National Cancer Center Hospital – sequence: 32 givenname: Noriko surname: Tanabe fullname: Tanabe, Noriko organization: National Cancer Center Hospital – sequence: 33 givenname: Kokichi surname: Sugano fullname: Sugano, Kokichi organization: Tochigi Cancer Center Research Institute – sequence: 34 givenname: Nobuyoshi orcidid: 0000-0003-4215-4385 surname: Hiraoka fullname: Hiraoka, Nobuyoshi organization: National Cancer Center Hospital – sequence: 35 givenname: Kenji orcidid: 0000-0002-3514-9927 surname: Tamura fullname: Tamura, Kenji organization: National Cancer Center Hospital – sequence: 36 givenname: Teruhiko surname: Yoshida fullname: Yoshida, Teruhiko organization: National Cancer Center Hospital – sequence: 37 givenname: Yasuhiro surname: Fujiwara fullname: Fujiwara, Yasuhiro organization: National Cancer Center – sequence: 38 givenname: Atsushi surname: Ochiai fullname: Ochiai, Atsushi organization: National Cancer Center – sequence: 39 givenname: Noboru surname: Yamamoto fullname: Yamamoto, Noboru organization: National Cancer Center Hospital – sequence: 40 givenname: Takashi orcidid: 0000-0002-5371-706X surname: Kohno fullname: Kohno, Takashi email: tkkohno@ncc.go.jp organization: National Cancer Center Research Institute |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30742731$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kc9uEzEQxi1URP_AgRdAlrjAIa299tq7HCpFEQWkShyAszXrnU1dOXZYe0GROPQR-ow8CU6TIqjAF480v-_TzHzH5CDEgIQ85-yUl3dmIZ1y0ar2ETniQrYzzZg6uKv1rGWiOiTHKV0zJpRs5RNyKJiWlRb8iPy4QEiuc97lDYXQ0ynv6jhQoGsI6GnGlF1Y0iGOlHNJLQSL48-bW0gpWgcZe7rEgIm6UETWu-AseJowb3Vv6JxexbR2GXwRdZAKn_LUb56SxwP4hM_2_wn5cvH28-L97PLjuw-L-eXM1kKUbWTFmw7aqtFK6lpAVSPvUQ9aNUL3HDvB266Gvkc5aGyrHgSIupM1H6DhrTgh5zvf9dStsLcY8gjerEe3gnFjIjjzdye4K7OM34ySUjdSFINXe4Mxfp3KOczKJYvel_vEKZmqYpVSitW8oC8foNdxGkNZr1BKCa4atqVe_DnR71HugynA2Q6wY0xpxMHYcr_s4nZA5w1nZhu9KdGbu-iL4vUDxb3pv9i9-3fncfN_0Czmn3aKXz9Dv80 |
| CitedBy_id | crossref_primary_10_2169_internalmedicine_1845_23 crossref_primary_10_1002_cam4_4725 crossref_primary_10_1007_s10147_023_02345_7 crossref_primary_10_1111_cas_15328 crossref_primary_10_1007_s10549_022_06822_x crossref_primary_10_1016_j_critrevonc_2021_103465 crossref_primary_10_1002_deo2_365 crossref_primary_10_3390_medicina59122111 crossref_primary_10_2958_suizo_35_313 crossref_primary_10_3390_healthcare9101395 crossref_primary_10_1093_jjco_hyac063 crossref_primary_10_1200_PO_22_00266 crossref_primary_10_1016_j_actbio_2024_05_037 crossref_primary_10_3999_jscpt_53_3_115 crossref_primary_10_1055_s_0044_1779275 crossref_primary_10_1111_pin_13170 crossref_primary_10_2482_haigan_59_1107 crossref_primary_10_1248_yakushi_19_00217_3 crossref_primary_10_1007_s10147_024_02616_x crossref_primary_10_1093_jjco_hyae002 crossref_primary_10_1159_000530790 crossref_primary_10_24060_2076_3093_2022_12_2_164_171 crossref_primary_10_2217_fon_2022_0122 crossref_primary_10_1007_s13577_022_00787_1 crossref_primary_10_2169_naika_110_1890 crossref_primary_10_5630_jans_44_208 crossref_primary_10_12677_ACM_2023_132256 crossref_primary_10_1007_s00262_019_02455_0 crossref_primary_10_5981_jjhnc_47_342 crossref_primary_10_1007_s10147_023_02360_8 crossref_primary_10_1111_1759_7714_14751 crossref_primary_10_1038_s41598_022_06885_2 crossref_primary_10_3390_cancers14143476 crossref_primary_10_5946_ce_2022_086 crossref_primary_10_1016_j_plabm_2024_e00369 crossref_primary_10_1007_s00428_021_03030_8 crossref_primary_10_3919_jjsa_80_1269 crossref_primary_10_1172_JCI126185 crossref_primary_10_1093_narcan_zcab008 crossref_primary_10_1200_PO_24_00437 crossref_primary_10_1371_journal_pone_0247090 crossref_primary_10_1111_cas_16446 crossref_primary_10_1007_s10147_020_01844_1 crossref_primary_10_1111_cas_16324 crossref_primary_10_1093_jjco_hyac046 crossref_primary_10_1038_s41379_020_0530_3 crossref_primary_10_1007_s12282_024_01656_5 crossref_primary_10_3390_cancers12071965 crossref_primary_10_1007_s10147_024_02483_6 crossref_primary_10_1097_MCG_0000000000002020 crossref_primary_10_3390_ijms22010240 crossref_primary_10_1002_cpt_1817 crossref_primary_10_1002_cam4_6498 crossref_primary_10_1200_OP_20_00131 crossref_primary_10_1200_PO_23_00681 crossref_primary_10_3390_ijms21103530 crossref_primary_10_1111_cas_15586 crossref_primary_10_1016_j_neo_2022_100834 crossref_primary_10_1136_bmjopen_2023_072472 crossref_primary_10_1016_j_bbrc_2021_11_063 crossref_primary_10_1111_cas_15249 crossref_primary_10_1111_cas_16338 crossref_primary_10_1038_s41598_021_99364_z crossref_primary_10_1111_cas_16342 crossref_primary_10_1371_journal_pone_0307580 crossref_primary_10_1016_j_pan_2024_12_012 crossref_primary_10_1111_cas_16102 crossref_primary_10_3390_jpm12030444 crossref_primary_10_4103_jpo_jpo_1_24 crossref_primary_10_1080_14737159_2024_2353696 crossref_primary_10_3390_jpm12050695 crossref_primary_10_1007_s12672_022_00574_2 crossref_primary_10_1371_journal_pone_0266947 crossref_primary_10_1016_j_jmoldx_2024_05_013 crossref_primary_10_2198_electroph_67_5 crossref_primary_10_1002_cam4_5349 crossref_primary_10_5981_jjhnc_48_330 crossref_primary_10_1186_s12885_022_09949_8 crossref_primary_10_1002_cam4_5588 crossref_primary_10_23922_jarc_2021_009 crossref_primary_10_1016_j_esmoop_2024_102981 crossref_primary_10_17650_2686_9594_2022_12_3_26_35 crossref_primary_10_1111_pin_13086 crossref_primary_10_3390_cancers14102454 crossref_primary_10_3390_cancers16061184 crossref_primary_10_1111_cas_16334 crossref_primary_10_5227_skincancer_37_94 crossref_primary_10_2482_haigan_61_303 crossref_primary_10_1093_jrr_rrab009 crossref_primary_10_1002_dc_25306 crossref_primary_10_1007_s13402_021_00656_3 crossref_primary_10_1002_cam4_3619 crossref_primary_10_2183_pjab_96_023 crossref_primary_10_2169_naika_112_454 crossref_primary_10_1016_j_isci_2023_106695 crossref_primary_10_1007_s10147_024_02554_8 crossref_primary_10_1038_s41598_023_35703_6 crossref_primary_10_3390_cancers16162819 crossref_primary_10_3390_jpm12030413 crossref_primary_10_1111_den_14423 crossref_primary_10_1200_PO_19_00291 crossref_primary_10_1111_1759_7714_13839 crossref_primary_10_1111_cas_15951 crossref_primary_10_1097_PAS_0000000000001742 crossref_primary_10_1016_j_jtho_2021_07_027 crossref_primary_10_1007_s13577_023_01015_0 crossref_primary_10_1186_s12885_024_12261_2 crossref_primary_10_1016_j_gore_2021_100847 crossref_primary_10_1093_jjco_hyab159 crossref_primary_10_1038_s10038_019_0681_6 crossref_primary_10_3390_curroncol29100573 crossref_primary_10_1111_cas_14608 crossref_primary_10_1007_s11060_023_04411_6 crossref_primary_10_2152_jmi_70_154 crossref_primary_10_1007_s10147_023_02398_8 crossref_primary_10_1007_s10396_023_01403_x crossref_primary_10_3999_jscpt_54_3_162 crossref_primary_10_1007_s10147_023_02337_7 crossref_primary_10_1016_j_resinv_2023_08_005 crossref_primary_10_1002_jhbp_994 crossref_primary_10_1016_j_anl_2024_04_008 crossref_primary_10_1111_cas_14967 crossref_primary_10_3390_diagnostics13071275 crossref_primary_10_1007_s00535_022_01926_z crossref_primary_10_1158_2767_9764_CRC_23_0018 crossref_primary_10_1007_s11060_022_04074_9 crossref_primary_10_1016_j_esmoop_2024_104108 crossref_primary_10_1111_cas_16355 crossref_primary_10_3390_cancers12010221 crossref_primary_10_1007_s00535_023_02058_8 crossref_primary_10_1016_j_heliyon_2024_e37867 crossref_primary_10_46459_pmu_2020008 crossref_primary_10_1371_journal_pone_0266112 crossref_primary_10_1007_s12328_022_01703_8 crossref_primary_10_3390_cancers15235608 crossref_primary_10_1038_s41598_021_98527_2 crossref_primary_10_1111_cas_14754 crossref_primary_10_1080_07357907_2024_2343860 crossref_primary_10_5009_gnl19418 crossref_primary_10_1097_FPC_0000000000000476 crossref_primary_10_1007_s40291_021_00544_4 crossref_primary_10_1186_s12920_022_01230_y crossref_primary_10_2482_haigan_62_173 crossref_primary_10_1002_cncr_34717 crossref_primary_10_1007_s13577_022_00828_9 crossref_primary_10_1038_s44276_024_00046_w crossref_primary_10_2198_jelectroph_65_1 crossref_primary_10_1093_jalm_jfad069 crossref_primary_10_30683_1929_2279_2023_12_1 crossref_primary_10_1111_1759_7714_15330 crossref_primary_10_1007_s12072_024_10770_7 crossref_primary_10_1111_pin_13318 crossref_primary_10_1111_cas_15833 crossref_primary_10_3389_fgene_2024_1343720 crossref_primary_10_1111_cas_15717 crossref_primary_10_1111_cas_15837 crossref_primary_10_1200_PO_24_00284 crossref_primary_10_1038_s41598_022_08925_3 crossref_primary_10_4030_jjcs_46_639 crossref_primary_10_1002_cam4_7162 crossref_primary_10_1002_jgh3_12965 crossref_primary_10_1038_s41598_021_98275_3 crossref_primary_10_1016_j_oraloncology_2024_106807 crossref_primary_10_1111_cas_16130 crossref_primary_10_1016_j_resinv_2024_07_018 crossref_primary_10_1093_jjco_hyaa277 crossref_primary_10_1002_onco_13639 crossref_primary_10_1080_14737159_2020_1728256 crossref_primary_10_1111_cas_15504 crossref_primary_10_1111_jog_15240 crossref_primary_10_3892_br_2022_1516 crossref_primary_10_3390_cancers14153674 crossref_primary_10_1111_cas_16165 crossref_primary_10_1111_jcpt_13367 crossref_primary_10_1111_cas_15993 crossref_primary_10_1016_j_job_2022_02_004 crossref_primary_10_1111_1759_7714_14685 crossref_primary_10_1038_s41591_024_03244_8 crossref_primary_10_1016_j_jtocrr_2024_100691 crossref_primary_10_3389_fneur_2023_1270046 crossref_primary_10_1002_gcc_23143 crossref_primary_10_1007_s11523_022_00871_4 crossref_primary_10_1038_s41598_021_81475_2 crossref_primary_10_1093_biomethods_bpac014 crossref_primary_10_1016_j_ctarc_2023_100701 crossref_primary_10_1186_s12885_023_11442_9 crossref_primary_10_2482_haigan_60_887 crossref_primary_10_1002_cam4_7189 crossref_primary_10_2995_jacsurg_37_527 crossref_primary_10_1111_cas_16034 crossref_primary_10_1002_cam4_3383 crossref_primary_10_1016_j_medj_2021_02_006 crossref_primary_10_1002_hed_27587 crossref_primary_10_1038_s41598_022_08430_7 crossref_primary_10_3804_jjabcs_29_1 crossref_primary_10_1111_cas_15182 crossref_primary_10_1007_s10147_024_02497_0 crossref_primary_10_1200_PO_20_00048 crossref_primary_10_1007_s10549_020_05716_0 crossref_primary_10_1056_NEJMoa2030391 crossref_primary_10_1016_j_gore_2022_100993 crossref_primary_10_3390_cancers16081504 crossref_primary_10_1002_cnr2_2127 crossref_primary_10_3390_cancers14051119 crossref_primary_10_1093_jjco_hyaf011 crossref_primary_10_1111_cas_16065 crossref_primary_10_3390_life11080796 crossref_primary_10_2482_haigan_60_364 crossref_primary_10_53394_akd_1037771 crossref_primary_10_1111_cas_15651 crossref_primary_10_1016_j_ygyno_2019_10_022 crossref_primary_10_1254_fpj_22048 crossref_primary_10_1111_1759_7714_13694 crossref_primary_10_3390_ph16111591 crossref_primary_10_1016_j_anl_2023_04_006 crossref_primary_10_1038_s10038_023_01133_5 crossref_primary_10_7759_cureus_69366 crossref_primary_10_1002_ags3_12482 crossref_primary_10_3389_fonc_2021_732525 crossref_primary_10_1007_s11626_024_00983_3 crossref_primary_10_1111_cas_14674 crossref_primary_10_1111_cas_14552 crossref_primary_10_1111_cas_16058 crossref_primary_10_1002_cam4_70249 crossref_primary_10_1200_PO_21_00001 crossref_primary_10_5649_jjphcs_48_500 crossref_primary_10_1093_jjco_hyad066 crossref_primary_10_1038_s41598_021_90139_0 crossref_primary_10_1007_s10147_020_01831_6 crossref_primary_10_1200_PO_20_00383 crossref_primary_10_1111_pin_13029 crossref_primary_10_1016_j_eucr_2022_102210 crossref_primary_10_1111_cas_14583 crossref_primary_10_1186_s13256_022_03640_z crossref_primary_10_2169_naika_112_1706 crossref_primary_10_1186_s12935_020_1128_z crossref_primary_10_1111_1759_7714_14643 crossref_primary_10_1007_s13577_019_00291_z crossref_primary_10_3919_jjsa_84_265 crossref_primary_10_3925_jjtc_65_777 crossref_primary_10_1007_s13577_022_00671_y crossref_primary_10_1038_s41525_024_00394_z crossref_primary_10_1007_s10147_025_02713_5 crossref_primary_10_3390_diagnostics13061078 crossref_primary_10_1245_s10434_021_09856_5 crossref_primary_10_1373_clinchem_2019_303305 crossref_primary_10_1007_s10147_023_02439_2 crossref_primary_10_1038_s10038_022_01028_x crossref_primary_10_1111_pin_13385 crossref_primary_10_1002_gcc_23182 crossref_primary_10_1093_ajcp_aqad046 crossref_primary_10_3390_cancers13051121 crossref_primary_10_1016_j_oraloncology_2024_107079 crossref_primary_10_1038_s41416_023_02189_y crossref_primary_10_3892_or_2021_8168 crossref_primary_10_1186_s41021_020_0147_2 crossref_primary_10_1016_j_esmorw_2025_100114 crossref_primary_10_2482_haigan_64_792 crossref_primary_10_3892_mco_2023_2612 crossref_primary_10_1016_j_cancergen_2021_04_001 |
| Cites_doi | 10.1038/nm.4333 10.1111/cas.13730 10.1038/nature17676 10.1126/science.aaa1348 10.1186/s12943-016-0553-z 10.1111/cas.12941 10.14806/ej.17.1.200 10.1158/0008-5472.CAN-14-3282 10.1016/j.ccell.2018.12.009 10.18632/oncotarget.23765 10.1111/cas.13265 10.1002/cpt.505 10.1016/S1470-2045(15)70007-0 10.1093/nar/gkq929 10.1038/nature25480 10.1309/AJCPR88WDJJLDMBN 10.1038/gim.2016.190 10.1038/hgv.2015.50 10.1158/2159-8290.CD-15-0754 10.1016/j.neo.2015.03.004 10.1093/bioinformatics/btp324 10.1038/nrd.2016.68 10.1038/nm1114-1220 10.1056/NEJMoa1801946 10.1056/NEJMoa1406498 10.1101/gr.107524.110 10.1126/science.1239947 10.18632/oncotarget.17102 10.1038/nature24028 10.1016/j.cell.2017.09.048 10.1038/nbt.1754 10.1186/s13073-017-0424-2 10.1038/nature12477 10.1093/bioinformatics/btp698 10.1016/j.jmoldx.2016.10.002 10.1038/nm.2713 10.1007/s00439-017-1852-1 10.1111/cas.13486 10.1093/jnci/djj517 10.1093/nar/gkx1153 10.1038/ng.3375 10.1038/nbt.2696 10.1186/s13073-018-0547-0 10.1093/bioinformatics/btr446 10.1016/j.gde.2017.02.004 |
| ContentType | Journal Article |
| Copyright | 2019 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. 2019. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2019 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. – notice: 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. – notice: 2019. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1111/cas.13969 |
| DatabaseName | Wiley Online Library Open Access - NZ CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni) Medical Database Biological Science Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | SUNAMI et al |
| EISSN | 1349-7006 |
| EndPage | 1490 |
| ExternalDocumentID | PMC6447843 30742731 10_1111_cas_13969 CAS13969 |
| Genre | article Journal Article |
| GeographicLocations | United States--US Japan |
| GeographicLocations_xml | – name: United States--US – name: Japan |
| GrantInformation_xml | – fundername: Japan Agency for Medical Research and Development funderid: JP18kk0205004, JP18lk1403003 – fundername: National Cancer Center Research and Development Fund funderid: 27‐A‐1, 30‐A‐6 – fundername: National Cancer Center Research and Development Fund grantid: 27-A-1, 30-A-6 – fundername: Japan Agency for Medical Research and Development grantid: JP18kk0205004, JP18lk1403003 – fundername: National Cancer Center Research and Development Fund grantid: 27‐A‐1, 30‐A‐6 |
| GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OC 24P 29B 2WC 31~ 36B 3O- 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52W 52X 53G 5GY 5HH 5LA 5VS 66C 7.U 702 7PT 8-0 8-1 8-3 8-4 8-5 8FE 8FH 8UM 930 A01 A03 AAHHS AAZKR ABCQN ABEML ACCFJ ACCMX ACSCC ACXQS ADBBV ADKYN ADPDF ADZMN ADZOD AEEZP AENEX AEQDE AFBPY AFEBI AFFNX AFKRA AFPKN AFZJQ AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU BAWUL BBNVY BCNDV BENPR BFHJK BHPHI BY8 CAG CCPQU COF CS3 D-6 D-7 D-E D-F DIK DR2 DU5 E3Z EBS EJD EMB EMOBN EX3 F00 F01 F04 F5P FIJ GODZA GROUPED_DOAJ HCIFZ HF~ HOLLA HYE HZI HZ~ IAO IHR IPNFZ ITC IX1 J0M K.9 K48 KQ8 LC2 LC3 LH4 LK8 LP6 LP7 LW6 M7P MK4 N04 N05 N9A O9- OIG OK1 OVD P2P P2X P2Z P4B P4D PIMPY PROAC Q11 ROL RPM RX1 SJN SUPJJ SV3 TEORI UB1 W8V WIN WOW WQJ WRC WXI X7M XG1 ZXP ~IA ~WT 7X7 88E 8FI 8FJ AAFWJ AAYXX ABUWG CITATION FYUFA HMCUK M1P PHGZM PHGZT PSQYO UKHRP AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM PJZUB PPXIY PQGLB 3V. 7XB 8FK AZQEC DWQXO GNUQQ K9. PKEHL PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c5339-74218ba928764753a25e1de7f76837d1eb319b5adde4f7e92da3a35b451fa8193 |
| IEDL.DBID | 7X7 |
| ISSN | 1347-9032 1349-7006 |
| IngestDate | Thu Aug 21 17:19:47 EDT 2025 Tue Aug 05 11:32:37 EDT 2025 Wed Aug 13 07:15:15 EDT 2025 Mon Jul 21 06:02:47 EDT 2025 Thu Apr 24 23:00:55 EDT 2025 Tue Jul 01 01:31:05 EDT 2025 Wed Jan 22 16:29:09 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | clinical sequencing NCC Oncopanel gene panel test actionable gene aberration insurance reimbursement |
| Language | English |
| License | Attribution-NonCommercial 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5339-74218ba928764753a25e1de7f76837d1eb319b5adde4f7e92da3a35b451fa8193 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-2557-8170 0000-0001-5807-8458 0000-0001-7098-3311 0000-0002-5371-706X 0000-0003-4215-4385 0000-0002-3514-9927 0000-0001-8972-9217 0000-0001-7251-7920 |
| OpenAccessLink | https://www.proquest.com/docview/2266316801?pq-origsite=%requestingapplication% |
| PMID | 30742731 |
| PQID | 2266316801 |
| PQPubID | 4378882 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6447843 proquest_miscellaneous_2202666051 proquest_journals_2266316801 pubmed_primary_30742731 crossref_citationtrail_10_1111_cas_13969 crossref_primary_10_1111_cas_13969 wiley_primary_10_1111_cas_13969_CAS13969 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | April 2019 2019-04-00 2019-Apr 20190401 |
| PublicationDateYYYYMMDD | 2019-04-01 |
| PublicationDate_xml | – month: 04 year: 2019 text: April 2019 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Tokyo – name: Hoboken |
| PublicationTitle | Cancer science |
| PublicationTitleAlternate | Cancer Sci |
| PublicationYear | 2019 |
| Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc |
| References | 2015; 2 2009; 25 2017; 42 2017; 8 2015; 17 2015; 16 2006; 98 2016; 107 2015; 75 2015; 144 2019; 35 2013; 500 2017; 23 2017; 171 2016; 100 2012; 18 2018; 109 2014; 371 2015; 348 2017; 550 2011; 17 2011; 39 2016; 15 2017; 9 2014; 20 2018; 46 2017; 108 2018; 9 2016; 6 2010; 20 2015; 47 2010; 26 2018; 2 2018; 555 2013; 31 2018; 137 2018; 378 2017; 19 2016; 534 2011; 27 2018; 10 2011; 29 2014; 343 e_1_2_7_6_1 e_1_2_7_5_1 e_1_2_7_4_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_16_1 e_1_2_7_40_1 e_1_2_7_2_1 e_1_2_7_15_1 e_1_2_7_41_1 e_1_2_7_14_1 e_1_2_7_42_1 e_1_2_7_13_1 e_1_2_7_43_1 e_1_2_7_12_1 e_1_2_7_44_1 e_1_2_7_11_1 e_1_2_7_45_1 e_1_2_7_10_1 e_1_2_7_46_1 e_1_2_7_47_1 e_1_2_7_26_1 e_1_2_7_28_1 Honda T (e_1_2_7_27_1) 2018; 2 e_1_2_7_29_1 e_1_2_7_30_1 e_1_2_7_25_1 e_1_2_7_31_1 e_1_2_7_24_1 e_1_2_7_32_1 e_1_2_7_23_1 e_1_2_7_33_1 e_1_2_7_22_1 e_1_2_7_34_1 e_1_2_7_21_1 e_1_2_7_35_1 e_1_2_7_20_1 e_1_2_7_36_1 e_1_2_7_37_1 e_1_2_7_38_1 e_1_2_7_39_1 |
| References_xml | – volume: 8 start-page: 41474 year: 2017 end-page: 41486 article-title: A systematic review and meta‐analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer publication-title: Oncotarget – volume: 29 start-page: 24 year: 2011 end-page: 26 article-title: Integrative genomics viewer publication-title: Nat Biotechnol – volume: 2 start-page: 15050 year: 2015 article-title: iJGVD: an integrative Japanese genome variation database based on whole‐genome sequencing publication-title: Hum Genome Var – volume: 27 start-page: 2601 year: 2011 end-page: 2602 article-title: ContEst: estimating cross‐contamination of human samples in next‐generation sequencing data publication-title: Bioinformatics – volume: 348 start-page: 124 year: 2015 end-page: 128 article-title: Cancer immunology. Mutational landscape determines sensitivity to PD‐1 blockade in non‐small cell lung cancer publication-title: Science – volume: 109 start-page: 507 year: 2018 end-page: 512 article-title: Implementation of “clinical sequencing” in cancer genome medicine in Japan publication-title: Cancer Sci – volume: 26 start-page: 589 year: 2010 end-page: 595 article-title: Fast and accurate long‐read alignment with Burrows‐Wheeler transform publication-title: Bioinformatics – volume: 19 start-page: 4 year: 2017 end-page: 23 article-title: Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists publication-title: J Mol Diagn – volume: 16 start-page: 251 year: 2015 end-page: 252 article-title: Japanese universal health care faces a crisis in cancer treatment publication-title: Lancet Oncol – volume: 20 start-page: 1297 year: 2010 end-page: 1303 article-title: The Genome Analysis Toolkit: a MapReduce framework for analyzing next‐generation DNA sequencing data publication-title: Genome Res – volume: 137 start-page: 31 year: 2018 end-page: 37 article-title: Actionable secondary findings from whole‐genome sequencing of 954 East Asians publication-title: Hum Genet – volume: 371 start-page: 2189 year: 2014 end-page: 2199 article-title: Genetic basis for clinical response to CTLA‐4 blockade in melanoma publication-title: N Engl J Med – volume: 107 start-page: 713 year: 2016 end-page: 720 article-title: Gene aberrations for precision medicine against lung adenocarcinoma publication-title: Cancer Sci – volume: 378 start-page: 2093 year: 2018 end-page: 2104 article-title: Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden publication-title: N Engl J Med – volume: 25 start-page: 1754 year: 2009 end-page: 1760 article-title: Fast and accurate short read alignment with Burrows‐Wheeler transform publication-title: Bioinformatics – volume: 39 start-page: D945 year: 2011 end-page: D950 article-title: COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer publication-title: Nucleic Acids Res – volume: 144 start-page: 667 year: 2015 end-page: 674 article-title: Occult specimen contamination in routine clinical next‐generation sequencing testing publication-title: Am J Clin Pathol – volume: 98 start-page: 1760 year: 2006 end-page: 1763 article-title: Lack of progress in teen and young adult cancers concerns researchers, prompts study publication-title: J Natl Cancer Inst – volume: 23 start-page: 703 year: 2017 end-page: 713 article-title: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients publication-title: Nat Med – volume: 15 start-page: 293 year: 2016 end-page: 294 article-title: Evolution of frameworks for expediting access to new drugs in Japan publication-title: Nat Rev Drug Discovery – volume: 108 start-page: 1440 year: 2017 end-page: 1446 article-title: Clinical sequencing using a next‐generation sequencing‐based multiplex gene assay in patients with advanced solid tumors publication-title: Cancer Sci – volume: 19 start-page: 249 year: 2017 end-page: 255 article-title: Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics publication-title: Genet Med – volume: 47 start-page: 1003 year: 2015 end-page: 1010 article-title: Genomic spectra of biliary tract cancer publication-title: Nat Genet – volume: 35 start-page: 177 year: 2019 end-page: 190 article-title: Targeting the vulnerability of glutathione metabolism in ARID1A‐deficient cancers publication-title: Cancer Cell – volume: 100 start-page: 626 year: 2016 end-page: 632 article-title: Pharmaceuticals Licensing and Reimbursement in the European Union, United States, and Japan publication-title: Clin Pharmacol Ther – volume: 550 start-page: 128 year: 2017 end-page: 132 article-title: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage‐specific tumours publication-title: Nature – volume: 17 start-page: 385 year: 2015 end-page: 399 article-title: Development and validation of a scalable next‐generation sequencing system for assessing relevant somatic variants in solid tumors publication-title: Neoplasia – volume: 10 start-page: 44 year: 2018 article-title: A computational tool to detect DNA alterations tailored to formalin‐fixed paraffin‐embedded samples in cancer clinical sequencing publication-title: Genome Med – volume: 18 start-page: 521 year: 2012 end-page: 528 article-title: A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer publication-title: Nat Med – volume: 343 start-page: 189 year: 2014 end-page: 193 article-title: Mutational analysis reveals the origin and therapy‐driven evolution of recurrent glioma publication-title: Science – volume: 171 start-page: 1042 year: 2017 end-page: 1056 article-title: Comprehensive analysis of hypermutation in human cancer publication-title: Cell – volume: 17 start-page: 10 year: 2011 end-page: 12 article-title: Cutadapt removes adapter sequences from high‐throughput sequencing reads publication-title: EMBnet Journal – volume: 42 start-page: 56 year: 2017 end-page: 67 article-title: Mammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities publication-title: Curr Opin Genet Dev – volume: 555 start-page: 321 year: 2018 end-page: 327 article-title: The landscape of genomic alterations across childhood cancers publication-title: Nature – volume: 500 start-page: 415 year: 2013 end-page: 421 article-title: Signatures of mutational processes in human cancer publication-title: Nature – volume: 6 start-page: 430 year: 2016 end-page: 445 article-title: Targeting p300 addiction in CBP‐deficient cancers causes synthetic lethality by apoptotic cell death due to abrogation of MYC expression publication-title: Cancer Discov – volume: 31 start-page: 1023 year: 2013 end-page: 1031 article-title: Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing publication-title: Nat Biotechnol – volume: 20 start-page: 1220 year: 2014 end-page: 1221 article-title: Tumor sequencing takes off, but insurance reimbursement lags publication-title: Nat Med – volume: 534 start-page: 47 year: 2016 end-page: 54 article-title: Landscape of somatic mutations in 560 breast cancer whole‐genome sequences publication-title: Nature – volume: 15 start-page: 73 year: 2016 article-title: Comprehensive screening of target molecules by next‐generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials publication-title: Mol Cancer – volume: 9 start-page: 6228 year: 2018 end-page: 6237 article-title: Gene aberration profile of tumors of adolescent and young adult females publication-title: Oncotarget – volume: 109 start-page: 2980 year: 2018 end-page: 2985 article-title: Clinical practice guidance for next‐generation sequencing in cancer diagnosis and treatment (Edition 1.0) publication-title: Cancer Sci – volume: 46 start-page: D1062 year: 2018 end-page: d7 article-title: ClinVar: improving access to variant interpretations and supporting evidence publication-title: Nucleic Acids Res – volume: 2 start-page: 1481 year: 2018 end-page: 24 article-title: Deleterious pulmonary surfactant system gene mutations in lung adenocarcinomas associated with usual interstitial pneumonia publication-title: JCO Precis Oncol – volume: 9 start-page: 34 year: 2017 article-title: Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden publication-title: Genome Med – volume: 75 start-page: 2264 year: 2015 end-page: 2271 article-title: Development of lung adenocarcinomas with exclusive dependence on oncogene fusions publication-title: Can Res – ident: e_1_2_7_4_1 doi: 10.1038/nm.4333 – ident: e_1_2_7_10_1 doi: 10.1111/cas.13730 – ident: e_1_2_7_32_1 doi: 10.1038/nature17676 – ident: e_1_2_7_7_1 doi: 10.1126/science.aaa1348 – ident: e_1_2_7_11_1 doi: 10.1186/s12943-016-0553-z – volume: 2 start-page: 1481 year: 2018 ident: e_1_2_7_27_1 article-title: Deleterious pulmonary surfactant system gene mutations in lung adenocarcinomas associated with usual interstitial pneumonia publication-title: JCO Precis Oncol – ident: e_1_2_7_30_1 doi: 10.1111/cas.12941 – ident: e_1_2_7_15_1 doi: 10.14806/ej.17.1.200 – ident: e_1_2_7_26_1 doi: 10.1158/0008-5472.CAN-14-3282 – ident: e_1_2_7_45_1 doi: 10.1016/j.ccell.2018.12.009 – ident: e_1_2_7_25_1 doi: 10.18632/oncotarget.23765 – ident: e_1_2_7_3_1 doi: 10.1111/cas.13265 – ident: e_1_2_7_46_1 doi: 10.1002/cpt.505 – ident: e_1_2_7_12_1 doi: 10.1016/S1470-2045(15)70007-0 – ident: e_1_2_7_18_1 doi: 10.1093/nar/gkq929 – ident: e_1_2_7_34_1 doi: 10.1038/nature25480 – ident: e_1_2_7_40_1 doi: 10.1309/AJCPR88WDJJLDMBN – ident: e_1_2_7_20_1 doi: 10.1038/gim.2016.190 – ident: e_1_2_7_22_1 doi: 10.1038/hgv.2015.50 – ident: e_1_2_7_43_1 doi: 10.1158/2159-8290.CD-15-0754 – ident: e_1_2_7_39_1 doi: 10.1016/j.neo.2015.03.004 – ident: e_1_2_7_13_1 doi: 10.1093/bioinformatics/btp324 – ident: e_1_2_7_9_1 doi: 10.1038/nrd.2016.68 – ident: e_1_2_7_8_1 doi: 10.1038/nm1114-1220 – ident: e_1_2_7_33_1 doi: 10.1056/NEJMoa1801946 – ident: e_1_2_7_6_1 doi: 10.1056/NEJMoa1406498 – ident: e_1_2_7_21_1 doi: 10.1101/gr.107524.110 – ident: e_1_2_7_36_1 doi: 10.1126/science.1239947 – ident: e_1_2_7_29_1 doi: 10.18632/oncotarget.17102 – ident: e_1_2_7_42_1 doi: 10.1038/nature24028 – ident: e_1_2_7_35_1 doi: 10.1016/j.cell.2017.09.048 – ident: e_1_2_7_17_1 doi: 10.1038/nbt.1754 – ident: e_1_2_7_5_1 doi: 10.1186/s13073-017-0424-2 – ident: e_1_2_7_37_1 doi: 10.1038/nature12477 – ident: e_1_2_7_14_1 doi: 10.1093/bioinformatics/btp698 – ident: e_1_2_7_23_1 doi: 10.1016/j.jmoldx.2016.10.002 – ident: e_1_2_7_28_1 doi: 10.1038/nm.2713 – ident: e_1_2_7_47_1 doi: 10.1007/s00439-017-1852-1 – ident: e_1_2_7_2_1 doi: 10.1111/cas.13486 – ident: e_1_2_7_44_1 doi: 10.1093/jnci/djj517 – ident: e_1_2_7_24_1 doi: 10.1093/nar/gkx1153 – ident: e_1_2_7_31_1 doi: 10.1038/ng.3375 – ident: e_1_2_7_38_1 doi: 10.1038/nbt.2696 – ident: e_1_2_7_16_1 doi: 10.1186/s13073-018-0547-0 – ident: e_1_2_7_19_1 doi: 10.1093/bioinformatics/btr446 – ident: e_1_2_7_41_1 doi: 10.1016/j.gde.2017.02.004 |
| SSID | ssj0036494 |
| Score | 2.654376 |
| Snippet | Next‐generation sequencing (NGS) of tumor tissue (ie, clinical sequencing) can guide clinical management by providing information about actionable gene... Next‐generation sequencing ( NGS ) of tumor tissue (ie, clinical sequencing) can guide clinical management by providing information about actionable gene... Next-generation sequencing (NGS) of tumor tissue (ie, clinical sequencing) can guide clinical management by providing information about actionable gene... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1480 |
| SubjectTerms | actionable gene aberration Adult Aged Biomarkers, Tumor Cancer Cancer therapies Clinical medicine clinical sequencing Clinical trials Computational Biology - methods Consent Deoxyribonucleic acid DNA DNA Copy Number Variations Drugs Female Gene Expression Profiling - methods gene panel test Genes Genes, Neoplasm Genetic counseling Genomics Genomics - methods High-Throughput Nucleotide Sequencing Hospitals Humans Impact tests insurance reimbursement Laboratories Male Middle Aged Molecular Targeted Therapy Mutation NCC Oncopanel Neoplasms - diagnosis Neoplasms - drug therapy Neoplasms - genetics Neoplasms - mortality Next-generation sequencing Oncology Original Patients Physicians Prognosis R&D Research & development Solid tumors Studies Treatment Outcome Tumors |
| SummonAdditionalLinks | – databaseName: Wiley Online Library - Core collection (SURFmarket) dbid: DR2 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwELYQB9QLrxbYQpGLeugliMSOE9PTCoFWSPRQuhIHpMivwIpVttrHAcSBn9Df2F_CjONELA8J9RbJYyVxZuzvc8bfEPItMVaWGgLJGpNH3DgZaYC1kckssIk8scxLCp39FL0-P71ILxbIj-YsTK0P0W64YWT4-RoDXOnJkyDHkmAAXwQe3sNcLQREv1rpKCa4rAva8iySBywJqkKYxdP2nF-LXgDMl3mST_GrX4BOVshl8-h13snN_myq983dM1XH_3y3VbIcgCnt1p60RhZctU6WzsKv94_kHsBiSKW9paqyFDzWX49KqijMKW5IpyjZUV1RAMIUGBA16FLjfw9_VXACZ-kVTq50UEGn5lQmnTiffX1Iu_Q61DGBTrjAWur1bz-R_snx76NeFEo3RAbwo4yAcMe5VhL4mODAiFSSuti6rAR2wzIbA4WPpU5xcuVl5mRiFVMs1TyNSwUghW2QxWpUuS1CBVNCpQZ4Ta65lVbJ3CojjE516XKlOuR78xELE3TNsbzGsGj4DYxm4UezQ_Za0z-1mMdrRjuNJxQhnicFgFSBJb4O4g752jZDJOLvFRjh0QxtgM8KoIdgs1k7TnsXhlsQGYOWbM6lWgNU-Z5vqQbXXu0bAGuWcwav6T3m7Qcvjrrn_uLz-023yQdAgLJORdohi9PxzH0BlDXVuz6cHgFuuCdv priority: 102 providerName: Wiley-Blackwell |
| Title | Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcas.13969 https://www.ncbi.nlm.nih.gov/pubmed/30742731 https://www.proquest.com/docview/2266316801 https://www.proquest.com/docview/2202666051 https://pubmed.ncbi.nlm.nih.gov/PMC6447843 |
| Volume | 110 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwEB7xkKpeEKUPtqUrU3HoJSqJnTjmUm0RCCGBEBRpb5FfASSUBXY5VOLAT-hv5Jcw4zgpiLaXKJInymPG9vfZk28ANjLrVG2wIzlry0RYrxKDsDax0iGbKDPHg6TQwWGxdyr2x_k4LrhNY1plNyaGgdpNLK2Rf0OYUFCRpc30-9V1QlWjaHc1ltCYh0WSLqOoluOecPFCqLaorZCJ2uRZVBaiTB4qKIbgh_Kcn85HL0Dmy1zJpxg2TEK7y7AU0SMbte5-A3O-WYFXB3F__C3cIaKL-a6_mG4cw7AK55OaaYYd31-yGelqNGcM0SpDmsIs-f3m4f63jp7yjp3RCMguGryo-3WSTX1Ikd5iI3Yei43gRTQLOhZEat_B6e7Oz-29JNZXSCyCPJUgK05LoxWSpkIgbdFZ7lPnZY0UhEuXIs9OlclpBBS19CpzmmueG5GntUYkwd_DQjNp_CqwgutC5xbJR2mEU06r0mlbWJOb2pdaD-Br95UrG8XHqQbGZdWREHRIFRwygC-96VWruPE3o7XOVVXsdNPqT4gMYL1vxu5CeyD4hSe3ZIOks0AOhzYfWs_2d-G0TiA5tshnPu8NSIr7eUtzcR4kuRFVylJwfM0QHf9-8Gp7dBJOPv7_DT7Ba4Rmqs0RWoOF2c2t_4zwZ2aGMJ-Jo2GI9CEs_tg5PDoehqUEOh5nj0B0C5k |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwEB6VIgEXxD8LBQwCiUvUTezEMRJCq0K1pd1eaKW9Bf-lrVRlS3crVIkDj8CT8FA8CTOOE1oVuPUWyZM_z4zn--LJDMDLzDpVG3QkZ22ZCOtVYhDWJlY6ZBNl5ngoKTTZLsa74uM0ny7Bz-5fGEqr7NbEsFC7maVv5KsIEwpqsjRM3x19SahrFO2udi00WrPY9KdfkbLN3268R_2-yrL1Dztr4yR2FUgsQhuVIBdMS6MVUoVCIFjXWe5T52WNwJtLlyK7TJXJye9FLb3KnOaa50bkaa0xfnK87hW4ioF3SGRPTnuCxwuh2ia6QiZqyLNYyYgyh6iBGYItyqs-G_8ugNqLuZlnMXMIeuu34GZEq2zUmtdtWPLNHbg2ifvxd-EbIsiYX3vKdOMYmnE4ntVMM1xo_CFbUB2PZo8hOmZIi5glOzv-9f2HjpbhHdujFZcdNHhS96smm_uQkv2Gjdh-bG6CJ1HUdSwUxb0Hu5cy8_dhuZk1_iGwgutC5xbJTmmEU06r0mlbWJOb2pdaD-B1N8uVjcXOqefGYdWRHlRIFRQygBe96FFb4eNvQiudqqro5PPqj0kO4Hk_jO5Jey44w7MTkkGSWyBnRJkHrWb7u3D6LiE5jshzOu8FqPT3-ZHmYD-UAEcUK0vB8TWDdfz7wau10adw8Oj_b_AMro93JlvV1sb25mO4gbBQtflJK7C8OD7xTxB6LczTYO8MPl-2g_0G8bdDLw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bT9RAFD7BJSG-GO-uoo5GE18aaGfa6ZgYswIbENkQlYS3MrcCCekiu8SQ-OBP8Pf4c_wlnjOdrhDUN96azPQ25_Z9ndNzAF5k1qnaoCE5a8tEWK8Sg7A2sdIhmygzx0NJoa1Rsb4j3u_mu3Pws_sXhtIqO58YHLUbW_pGvoQwoaAmS8vpUh3TIrZXh2-PvyTUQYp2Wrt2Gq2KbPqzr0jfJm82VlHWL7NsuPZ5ZT2JHQYSizBHJcgL09JohbShEAjcdZb71HlZIwjn0qXINFNlcvIBopZeZU5zzXMj8rTWGEs5XvcazEtiRT2Yf7c22v7YxQFeCNW21BUyUcs8i3WNKI-I2pkh9KIs6_PR8BLEvZypeR5BhxA4vAk3InZlg1bZbsGcb27Dwlbcnb8D3xBPxmzbM6Ybx1Cpw_G4Zpqh2_FHbEpVPZp9hliZIUlilrTu5Nf3HzrqiXdsn_wvO2zwpO7HTTbxIUH7NRuwg9jqBE-iGOxYKJF7F3auZO3vQa8ZN_4BsILrQucWqU9phFNOq9JpW1iTm9qXWvfhVbfKlY2lz6kDx1HVUSAUSBUE0ofns6nHbb2Pv01a7ERVRZOfVH8UtA_PZsNorLQDgys8PqU5SHkLZJA4534r2dldOH2lkBxH5AWZzyZQIfCLI83hQSgIjphWloLjawbt-PeDVyuDT-Hg4f_f4CksoHFVHzZGm4_gOmJE1SYrLUJvenLqHyMOm5onUeEZ7F21jf0GWGNIyg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Feasibility+and+utility+of+a+panel+testing+for+114+cancer%E2%80%90associated+genes+in+a+clinical+setting%3A+A+hospital%E2%80%90based+study&rft.jtitle=Cancer+science&rft.au=Sunami%2C+Kuniko&rft.au=Ichikawa%2C+Hitoshi&rft.au=Kubo%2C+Takashi&rft.au=Kato%2C+Mamoru&rft.date=2019-04-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.issn=1347-9032&rft.eissn=1349-7006&rft.volume=110&rft.issue=4&rft.spage=1480&rft.epage=1490&rft_id=info:doi/10.1111%2Fcas.13969&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1347-9032&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1347-9032&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1347-9032&client=summon |